Patents by Inventor Daniel Getts

Daniel Getts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR CONDITIONING PATIENTS FOR CELL THERAPY
    Publication number: 20240139241
    Abstract: Compositions and methods for therapeutic use of engineered myeloid cells are described. Methods for increasing therapeutic effectiveness of immune cells by use of an immune cell inhibitory agent prior to therapy is described. Effective use of myeloid cells in combination therapy is described.
    Type: Application
    Filed: October 23, 2023
    Publication date: May 2, 2024
    Inventors: Daniel GETTS, Bruce J. McCreedy, JR., Michele Luise Gerber, Thomas Etienne Prod’homme
  • ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240139314
    Abstract: The present disclosure provides compositions and methods for making and using engineered myeloid cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, wherein the chimeric receptor is encoded by a recombinant nucleic acid.
    Type: Application
    Filed: October 13, 2023
    Publication date: May 2, 2024
    Inventors: Daniel GETTS, Yuxiao WANG
  • Engineered chimeric fusion protein compositions and methods of use thereof
    Patent number: 11944680
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Grant
    Filed: January 18, 2023
    Date of Patent: April 2, 2024
    Assignee: MYELOID THERAPEUTICS, INC.
    Inventors: Daniel Getts, Yuxiao Wang, Bruce McCreedy, Jr.
  • Methods and Compositions for Expression of Nucleic Acids in Cells
    Publication number: 20230374538
    Abstract: Compositions and methods for making and using engineered phagocytic cells that express a chimeric antigen receptor having an enhanced phagocytic activity for stable and durable expression are described and can be suitably used for immunotherapy in cancer or infection.
    Type: Application
    Filed: March 22, 2023
    Publication date: November 23, 2023
    Inventors: Daniel GETTS, Yuxiao WANG, Namita BISARIA, Inna SHCHERBAKOVA, William F. ROWLEY, JR.
  • METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION
    Publication number: 20230364265
    Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.
    Type: Application
    Filed: May 5, 2023
    Publication date: November 16, 2023
    Inventors: Daniel GETTS, Yuxiao Wang, Namita Bisaria, Inna Shcherbakova, Socheata Ly
  • METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION
    Publication number: 20230364266
    Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.
    Type: Application
    Filed: May 5, 2023
    Publication date: November 16, 2023
    Inventors: Daniel GETTS, Yuxiao Wang, Namita Bisaria, Inna Shcherbakova, Socheata Ly
  • COMPOSITIONS AND METHODS FOR AUTOIMMUNITY REGULATION
    Publication number: 20230338421
    Abstract: Provided herein are recombinant nucleic acids encoding T cell receptor (TCR) fusion proteins (TFPs), modified human immune cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including autoinmmune diseases.
    Type: Application
    Filed: January 8, 2021
    Publication date: October 26, 2023
    Inventors: Daniel GETTS, Robert HOFMEISTER, Patrick Alexander BAEUERLE, Dario GUTIERREZ, Dana GILMORE
  • COVALENT POLYMER-ANTIGEN CONJUGATED PARTICLES
    Publication number: 20230338576
    Abstract: The present invention provides compositions comprising tolerizing immune modified particles (TIMPs) and methods for using and making said TIMPs. In particular, carrier polymer is covalently conjugated with antigenic peptide before particle formation, which allows for exquisite control of particle size and antigen encapsulation (e.g., for use in eliciting induction of immunological tolerance).
    Type: Application
    Filed: October 24, 2022
    Publication date: October 26, 2023
    Inventors: Ryan Pearson, Daniel Getts, John Puisis, James Herrmann, Lonnie D. Shea
  • ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230303684
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Application
    Filed: January 20, 2023
    Publication date: September 28, 2023
    Inventors: Daniel Getts, Yuxiao Wang
  • ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230277659
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Application
    Filed: January 18, 2023
    Publication date: September 7, 2023
    Inventors: Daniel Getts, Yuxiao Wang, Bruce McCreedy, JR.
  • MONOCYTES INDUCING ANTIGEN-SPECIFIC TOLERANCE, ENGINEERED MONOCYTES, AND METHOD OF USE THEREOF
    Publication number: 20230263888
    Abstract: Methods and compositions for treating autoimmune diseases and conditions using engineered myeloid cells.
    Type: Application
    Filed: September 30, 2022
    Publication date: August 24, 2023
    Inventor: Daniel GETTS
  • Methods and compositions for genomic integration
    Patent number: 11672874
    Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: June 13, 2023
    Assignee: MYELOID THERAPEUTICS, INC.
    Inventors: Daniel Getts, Yuxiao Wang, Namita Bisaria, Inna Shcherbakova, Socheata Ly
  • METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION
    Publication number: 20230141052
    Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.
    Type: Application
    Filed: January 19, 2023
    Publication date: May 11, 2023
    Inventors: Daniel Getts, Yuxiao Wang, Namita Bisaria, Inna Shcherbakova, Socheata Ly
  • Engineered chimeric fusion protein compositions and methods of use thereof
    Patent number: 11628218
    Abstract: Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: April 18, 2023
    Assignee: MYELOID THERAPEUTICS, INC.
    Inventors: Daniel Getts, Yuxiao Wang, Bruce McCreedy, Jr.
  • METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION
    Publication number: 20230067484
    Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.
    Type: Application
    Filed: October 12, 2021
    Publication date: March 2, 2023
    Inventors: Daniel GETTS, Yuxiao Wang, Namita Bisaria, Inna Shcherbakova, Socheata Ly
  • THERAPEUTIC CELL COMPOSITIONS AND METHODS OF MANUFACTURING AND USE THEREOF
    Publication number: 20230046472
    Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.
    Type: Application
    Filed: June 10, 2022
    Publication date: February 16, 2023
    Inventors: Daniel Getts, Yuxiao Wang, Namita Bisaria, Kathryn Austgen, Caitlyn Anne Morrison Harvey, Patrick Mendes Tavares
  • METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION
    Publication number: 20220411817
    Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.
    Type: Application
    Filed: June 30, 2022
    Publication date: December 29, 2022
    Inventors: Daniel Getts, Yuxiao Wang, Namita Bisaria, Inna Shcherbakova, Socheata Ly
  • ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220378824
    Abstract: The present disclosure provides compositions and methods for making and using engineered phagocytic cells that express a chimeric antigen receptor having an enhanced phagocytic activity for immunotherapy in cancer or infection.
    Type: Application
    Filed: April 30, 2020
    Publication date: December 1, 2022
    Inventors: Daniel GETTS, Yuxiao Wang
  • Covalent polymer-antigen conjugated particles
    Patent number: 11510996
    Abstract: The present invention provides compositions comprising tolerizing immune modified particles (TIMPs) and methods for using and making said TIMPs. In particular, carrier polymer is covalently conjugated with antigenic peptide before particle formation, which allows for exquisite control of particle size and antigen encapsulation (e.g., for use in eliciting induction of immunological tolerance).
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: November 29, 2022
    Assignees: COUR PHARMACEUTICALS DEVELOPMENT COMPANY INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Ryan Pearson, Daniel Getts, John Puisis, James Herrmann, Lonnie D. Shea
  • METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION
    Publication number: 20220364110
    Abstract: Methods and composition for modulating a target genome and stable integration of a transgene of interest into the genome of a cell are disclosed.
    Type: Application
    Filed: June 30, 2022
    Publication date: November 17, 2022
    Inventors: Daniel Getts, Yuxiao Wang, Namita Bisaria, Inna Shcherbakova, Socheata Ly